During the interview, Mr. Burgess discussed Lattice’s recent contract wins, market opportunity, management team, and industry-leading secure communications technology. He also discussed the Company’s business outlook for 2013. The interview is available here:

http://thewallstreetanalysts.com/lattice-inc-otcbblttc-ceo-interview

Lattice is experiencing robust demand for its communications technology both domestically and abroad. Management expects its communications segment to grow 70% year-over-year in 2013. RedChip recently issued a research update on LTTC with a price target of $0.74, an upside of more than 500% from recent prices. Click here to view the update. You can also watch our recent “Money Report” interview with Mr. Burgess, below:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

The divestiture of these assets erases $282,000 worth of debt, adds $0.7 million in cash, and removes contract renewal risk associated with the current budgeting climate in Washington. The sale also frees up LTTC to focus on its fast-growing communications business, which is driving solid sales growth and margin improvement for the Company. Revenue generated by the communications division increased 64.7% year-over-year to $7.5 million for fiscal 2012.

LTTC expects 70% YoY sales growth in 2013 due to increasing domestic and international demand for its secured communications services. The Company’s new cloud-based service offering is expected to further drive sales growth. The system adds additional services to LTTC’s current offerings with minimal upfront cost to the customer.

Shares of LTTC currently trade around $0.10, but the stock is poised to move much higher as the Company expands its service offerings and moves into new markets. RedChip has issued a $0.71 price target on the stock. Learn more about LTTC by watching our recent “Money Report” interview with CEO Paul Burgess:

Interested parties can also dial into the Company’s first-quarter earnings conference call on Tuesday, May 14, 2013 at 2:00 p.m. ET (11:00 a.m. PT). Click here to view the dial-in information.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

The Company expects revenues to increase 34.7% year-over-year to $22.5 million, and net income to increase 200% to $4.2 million for the fiscal year ending March 31, 2014. Management believes PFIE will continue to find and capitalize on new opportunities in the U.S. oil and gas market.

PFIE’s strong historical revenue growth bodes well for the Company going forward. Between the fiscal years 2008 and 2012, annual revenues for the Company grew 269% from $4.3 million to $15.9 million. Since its inception in 2002, PFIE has grown from a small service company (delivering parts out of an old Buick) into the largest operator in the BMS space, servicing blue-chip multinationals such as ExxonMobil, Husky Oil, Devon Energy, Shell, and ConocoPhillips.

Current penetration for BMS technology in the U.S. is estimated at only 1% to 1.5% of a $2.5 billion to $6.7 billion overall market. With oil and gas operators increasingly focused on improving safety and efficiency, PFIE’s technology fills a huge, unmet market need.

To learn more about PFIE, watch CFO Andrew Limpert’s presentation from the recent RedChip Emerging Growth Showcase:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

One can make a fortune following in the footsteps of wise and highly successful investors such as John Pappajohn, the billionaire investor who has made hundreds of millions investing early in biotechs that are at the front edge of new technologies. Cancer Genetics (OTCQB: CGIX) recently went public raising $7 million at less than a $50 million market cap.   John Pappajohn believes that CGIX’s genetically based cancer diagnostic products are so advanced that he sees a company whose future holds a billion dollar or greater market cap, if it is not bought out before then.

His analysis is based on several comparables, two of which I will mention here: Decode Genetics, in the same business as CGIX, with less than $5 million in revenue, was bought out by Amgen (NASDAQ: AMGN) for $415 million;  Exact Sciences (NASDAQ: EXAS), with less than $5M in revenue, is trading at a $620 million market cap, over 150x sales.  CGIX, with a little over $4 million in revenue, is trading at 11x sales.  Few investors know the CGIX story.  The stock is inefficient. Buy microcaps before they are efficient.  That is how John Pappajohn made hundreds of millions of dollars.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

In the Fox interview, Ms. Powers described the importance of NW Bio’s DCVax cancer immunotherapy platform in mobilizing a patient’s whole immune system, and in targeting the full set of biomarkers on the cancer. You can watch the interview at http://video.foxbusiness.com/v/2344168115001/latest-advances-in-cancer-research.

In the Huffington Post and New York Financial Press interview, Ms. Powers outlined in more detail the process of creating the DCVax vaccine. She also discussed the significance of key regulatory approvals obtained in the U.S. and Europe, relating to Phase III clinical trials and Phase I/II trials. You can watch the Huffington Post interview at http://videos.huffingtonpost.com/business/nw-biotherapeutic-challenges-cancer-with-dc-vax-517764763.

In the International Business Times interview, Ms. Powers recounted the cost-saving potential of the DCVax platform, which positions NW Bio well in the face of the rapidly rising costs of less-effective conventional cancer treatments. You can watch the interview at http://tv.ibtimes.com/vaccine-cure-cancer-new-breakthrough-cancer-treatments-northwest-biotherapeutics-10585#share.

NWBO’s lead program is a 312-patient Phase III trial to treat glioblastoma multiforme, the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer and Phase I/II trials in multiple other cancers. NWBO’s cancer therapies have demonstrated the ability to significantly extend patient survival while eliminating the debilitating side effects associated with conventional treatments such as chemotherapy. To learn more about NWBO, watch our “Money Report” interview with CEO Linda Powers:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

MSLP caught the attention of Forbes earlier this year, in the article “Billionaire Pharmaceutical Entrepreneur Makes Bet On Fast Growing Supplement Manufacturer.” That billionaire is Dr. Phillip Frost, who led a $12 million round of financing for MSLP in February (as discussed in another Forbes article). You can see a brief list of Dr. Frost’s previous wins here.

Described by Forbes as “one of the rising stars” in the $32 billion nutritional supplement space, MSLP has achieved triple-digit annual revenue growth over the past four years, generating an estimated $78 million in 2012. The Company expects to reach $100 million in sales this year, bolstered by the strengthening international demand for its award-winning supplements. In 2012, international sales accounted for approximately 35% of total sales, up from 19% in 2011.

MSLP’s products are sold in more than 10,000 U.S. retail outlets and over 110 countries, and they consistently rank among Bodybuilding.com’s top 50 best sellers. The Company’s devoted customer base includes professional athletes such as Ultimate Fighting champion Benson “Smooth” Henderson, San Francisco 49ers quarterback Colin Kaepernick, Denver Broncos star wide receiver Eric Decker, and international rugby superstar Quade Cooper, all of whom recently signed endorsement deals with the Company. MSLP is also the official nutritional supplement sponsor of the Ultimate Fighting Championship, the world’s largest mixed martial arts organization.

One of the key drivers behind MSLP’s success is its powerful scientific team. The Company’s chief medical officer is a leading sports nutrition doctor, and MSLP’s team includes top former researchers from GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, the National Institutes of Health, and the FDA, as well as the former U.S. Assistant Surgeon General. All MSLP products are free of banned substances, and new products undergo rigorous testing at the Company’s Sports Science Center in Colorado.

The recent addition of former Office Depot executive Richard Estalella to MSLP’s management team should further strengthen the Company’s operations. Mr. Estalella helped grow Office Depot into a $9 billion company, and his track record of delivering strong cost savings and profit improvement will be an asset to MSLP as the Company continues its rapid growth trajectory.

In recent months, shares of MSLP have appreciated from the mid-$5 range to a 52-week high of $11.89. Currently trading around $9, MSLP is poised to deliver huge gains for investors who build a position today.

To learn more about MSLP, download RedChip’s research profile on the Company or watch our recent “Money Report” interview with CEO Brad Pyatt:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

During the online conference, company executives will offer inside views of their businesses through video presentations and interviews. Presenting companies range across a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare and more. A full list of presenting companies is available here.

The RedChip Emerging Growth Showcase will also feature interviews with investing and economic experts, including Bill Hench, portfolio manager for Royce & Associates, the investment adviser to The Royce Funds, an investment management firm focused on small-cap value investing; David Morgan, a precious metals expert and the publisher of “The Morgan Report” monthly newsletter; Ryan Jacob, chairman and chief investment officer of the Jacob Funds, a mutual fund management company; Thomas Landstreet, founder of Standard Research Corp., publisher of “Connecting the Dots,” an economic/investment research service exclusively serving the institutional investment community; Michael Corbett, CEO and portfolio manager at Perritt Capital Management, an investment firm specializing in small-cap and microcap companies; and Lyman “Buzz” Heidtke, portfolio manager of MidSouth Investment Fund, a leading microcap-focused fund.

To register to view the presentations, visit http://www.RedChip.com/virtualconference.

In the interview, Opportunist’s managing editor, Leslie Stone, talked with Mr. Gentry about RedChip’s small-cap research, investor relations services, and weekly television program, “The RedChip Money Report.” Opportunist is a resource of information for investors, the financial community and small businesses.

“I want to thank Opportunist for recognizing the work we’re doing in the small-cap space here at RedChip,” stated Mr. Gentry. “Our goal is to be the go-to investor relations firm for smaller-cap companies. That’s what we work for every day — to be the best in the business at what we do.”

Mr. Gentry is a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances on both CNBC and Fox Business News and has been a consultant to hundreds of public companies.

The interview is available online at: http://opportunistmagazine.com/dave-gentry-president-and-ceo-of-redchip-companies-inc-name/

The report highlights the investment potential of Document Security Systems (NYSE MKT: DSS), a provider of anti-counterfeit technology. DSS is in the process of merging with Lexington Technology Group, an IP monetization and commercialization company. Through its Bascom Research subsidiary, Lexington is currently engaged in patent litigation against Facebook, LinkedIn, and others, with a Markman hearing scheduled for October 2013.

Key highlights of the report include a history of IP monetization in the public and private sectors, background on DSS and the implications of its pending merger for shareholders, and delineation of risks and upside opportunities for the Company. According to Mr. Moreno, “Although there are many businesses focused on managing and monetizing intellectual property…none are structured to provide the overall level of value, diversification, and favorable risk-return profile as DSS.”

Investors can access the full white paper at http://www.diversifiedip.com/The_Emergence_of_DSS.pdf.

To learn more about DSS, watch our recent interview with incoming CEO Jeff Ronaldi:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

With millions of dollars at stake in each case, the ongoing patent war can create strong profit opportunities for investors. Companies such as Vringo, Acacia, and VirnetX have made millions specializing in patent litigation. A ruling in favor of the patent holder can cause a significant upswing in the stock, as exemplified by Vringo (NYSE MKT: VRNG), up more than 100% over the past year; and ParkerVision (NasdaqCM: PRKR), up 300% over the past year. A jury awarded Vringo $30 million last year in its suit against Google, and ParkerVision recently received the go-ahead to proceed with its case against communications giant Qualcomm. Investors who built early positions in Vringo and ParkerVision reaped huge gains as the stocks skyrocketed.

One candidate to become the next big patent stock is Document Security Systems, Inc. (NYSE MKT: DSS). DSS is in the process of merging with Lexington Technology Group, a private company focused on patent monetization and commercialization. The merger, which is expected to close in spring 2013, will bring $7 million in cash, a strong IP portfolio, and a management team with a proven track record in patent monetization. Incoming CEO Jeff Ronaldi has realized more than $160 million in gains on $12 million in patent investments over the past two decades. He played an instrumental role in successful patent verdicts against Genzyme, Citrix Systems, and Microsoft, the latter resulting in a $60 million settlement.

Lexington’s subsidiary, Bascom Research, is engaged in patent infringement suits against five defendants, including Facebook (NasdaqGS: FB) and LinkedIn (NYSE: LNKD). The suits allege that the defendants are violating key patents covering the manner in which users and application developers on social networks make connections between “objects” such as photos, people, events and pages. A key hearing in the case is set for October 2.

The value added by Lexington complements DSS’ strong underlying business. DSS provides anti-counterfeiting and authentication technology to Fortune 500 companies and government agencies. Counterfeiting costs the global economy an estimated $1 trillion each year, and DSS’ innovative technology portfolio provides a comprehensive solution with significant licensing opportunities. The Company is currently beta-testing AuthentiGuard, a suite of solutions that enable brand owners to identify counterfeits in real time by scanning products with their iPhones.

DSS currently trades in the $2 range, down from its 52-week high of $4.60. The merger with Lexington provides a huge near-term catalyst for the stock. A favorable court ruling or news of a settlement later this year could send the stock soaring, producing big gains for those who were savvy enough to invest at current prices. Don’t miss out. To learn more about DSS, watch our interview with Jeff Ronaldi, the Company’s incoming CEO:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

Traditionally viewed as a hedge against inflation and a safe haven in times of economic turmoil, gold is up over 80 percent since the end of 2008. One way for investors to play the bull run in gold is Pan American Goldfields (OTCQB: MXOM), a Canadian junior mining company.

MXOM is generating cash flow from pilot production at its Cieneguita mine in Mexico’s Sierra Madre, which hosts a majority of Mexico’s gold and silver deposits. A recent mineral resource estimate shows measured and indicated resources of 1.26 million ounces au eq. and a further 700,000 au eq. inferred. The Company is currently mining within an inferred area and recovering more than twice the average grade. The mine has a higher-grade core, which is expected to accelerate the payback and improve the internal rate of return, which is expected to be at least over 30% to possibly more than 40%.”

The Cieneguita mine is currently operating under an agreement with partner Minera Rio Tinto, with production averaging over 500 tons per day. Engineering firm M3 is conducting a Preliminary Economic Assessment for a much larger operation, with a scoping study expected to be completed in April 2013. M3 is including measured, indicated and inferred resources in designing the size of the mill, which is expected to be 15,000 to 17,000 tons per day, equating to an annual production level of about 150,000 ounces au. eq. Should the Company reach this production level, MXOM could earn a net cash flow of nearly $134 million annually (based on $1,600 gold and $30 silver and a $600 per ounce eq. cash cost).

On an enterprise value to resource basis, the stock currently trades at a steep discount to its peer group average. RedChip initiated coverage of MXOM with a target price of $1.02, an upside of nearly 400% from recent prices. It’s important to note that this price target was issued at a time when the Company was only forecasting a 100,000 ounces au. eq. operation. With production underway and the PEA results just around the corner, now is a great time for investors to build a position in MXOM.

Those who want to learn more about MXOM can participate in the Company’s live webinar and conference call on Tuesday, March 26, 2013 at 1:15 p.m. Pacific time (4:15 p.m. ET). Management will be available to discuss its latest metallurgical testing and mineral resource results, and to answer questions from investors. Instructions on how to access the call are available here.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

During use, glycols become contaminated and unusable, producing a vast amount of waste glycol—over 700 million gallons per year in the U.S. alone. Current recycling methods are only effective for used antifreeze. Even with this technology, only 12% of used antifreeze waste is formulated into recycled antifreeze. Although the Environmental Protection Agency classifies waste glycol as a hazardous material, most waste glycol is disposed of without documentation. Improperly disposed glycols can leach into the soil and contaminate groundwater, endangering the environment.

Manufacturers in the other four waste-producing industries (textile, airline, medical, and HVAC) have no viable way to recycle used glycols into Type 1 (virgin-equivalent) material—until now. GlyEco (OTCQB: GLYE), a green chemistry company, is rolling out a breakthrough recycling technology that addresses this $25 billion unmet market need.

GLYE’s patent-pending technology enables used glycols from all five major waste-producing industries to be recycled into Type 1 materials repeatedly. The Company’s GlyEco Technology™ offers a 20% to 50% reduction in processing costs over currently utilized glycol recycling methods.

The Company is aggressively expanding its processing capacity to meet customer needs. GLYE acquired five profitable recyclers in 2012 and plans to acquire additional facilities in 2013. The Company plans to retrofit the facilities in the months ahead to make them capable of producing Type 1 materials.

GLYE is partnered with ethylene waste collectors and polyester manufacturing companies in multiple countries, and is making inroads with sources of waste ethylene glycol in South America and Asia. These existing relationships, as well as GLYE’s relationship with MEGlobal, a joint venture between Dow Chemical and Kuwait-based PIC, should provide the Company with a steady source of revenue once its technology is implemented.

GLYE is a first mover in the glycol recycling market with limited competition from established ethylene glycol producers. The Company is positioned for significant share price growth as it rolls out its proprietary technology in the months ahead. Trading in the low $1 range, GLYE provides investors with a compelling profit opportunity. To learn more about GLYE, watch our “RedChip Money Report” interview with Chairman and CEO John Lorenz:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

The article discusses MSLP’s recent $12 million round of financing, led by billionaire investor Dr. Phillip Frost. Forbes also interviewed MSLP’s founder and CEO, former NFL player Bradley Pyatt, who discusses the Company’s origins, business strategy, and award-winning supplement products.

As we previously discussed, MSLP is a rapidly growing player in the $30 billion U.S. nutritional supplements market. Its products are sold in more than 10,000 U.S. retail outlets and over 110 countries. The Company has achieved triple-digit annual revenue growth over the past four years, generating an estimated $78 million in 2012. Debt-free and moving toward profitability, MSLP is an exciting opportunity for investors.

To learn more about MSLP, watch our recent “Money Report” interview with Mr. Pyatt:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

As the U.S. moves toward energy self-sufficiency, domestic oil and gas producers face mounting pressure to improve safety, meet environmental standards, and increase efficiency. Profire Energy (OTCBB: PFIE), a technology company and leading provider of burner management systems (BMS) to oil and gas companies, fills a critical market void. The Company’s products provide a safe and efficient solution for re-ignition and temperature regulation for use on processing vessels in the oil and gas industry.

In order to process the oil or gas, these vessels require heat provided by a burner. The flame occasionally extinguishes, creating production inefficiencies. Traditional methods for reigniting failed flames include using a rag tied to a stick, an antiquated method that puts the technician in danger. Profire’s BMS technology is able to quickly and safely reignite a failed flame, minimizing production loss and keeping employees safe. The Company’s technology meets U.S. Environmental Protection Agency standards, and optimizes efficiency by decreasing waste heat and fuel consumption.

With the expectation of increasing worker safety initiatives and environmental regulation, PFIE is poised to benefit as oil and gas companies are required to maintain compliance. Oil and gas companies will need to purchase the type of products made by PFIE, or risk facing costly fines. PFIE’s high-quality products have attracted top multinational clients such as Exxon Mobil, Husky Oil, Devon Energy, Shell, and ConocoPhillips.

Current penetration for BMS technology in the U.S. is estimated at only 1% to 1.5% of a $2.5 billion to $6.7 billion overall market. PFIE has a strong first-mover advantage and is the largest operator in the space. The Company’s competitors are small, private regional companies, the largest of which only generates about one-third of PFIE’s sales volume.

PFIE grew revenues 98% and net income 88% year-over-year for the fiscal year ended March 31, 2012. Following the Company’s strong sales growth in western Canada, PFIE is now expanding its U.S. sales efforts, opening offices in Texas and Utah to serve new and existing customers in these major oil and gas hubs. The Company also added a distribution channel in Brazil, South America’s largest economy. Trading under $2, PFIE is an exciting opportunity for investors to profit from America’s energy boom.

To learn more about PFIE, watch our recent “Money Report” interview with Andrew Limpert, the Company’s chief financial officer.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

Therapeutic vaccines offer one of the most promising treatment pathways in cancer immunotherapy. GlobalData, a leading market research firm, expects the global market for therapeutic cancer vaccines to grow from $48.0 million in 2010 to $4.9 billion by the end of 2018, a compound annual growth rate of 78.1%.

One immunotherapy company to watch is Northwest Biotherapeutics (NASDAQ: NWBO). NWBO uses dendritic cells, the starter engine of the immune system, in the formulation of its DCVax personalized cancer vaccines. Dendritic cells are extracted from the patient’s body and loaded with tumor biomarkers or “antigens,” creating a personalized therapeutic vaccine. In clinical trials, the Company’s cancer vaccines demonstrated the ability to significantly extend both time to recurrence and survival, while providing a superior quality of life with no debilitating side effects when compared with current treatments such as chemotherapy.

NWBO has two cancer vaccines in Phase III clinical trials, the final phase of testing before product approval. The Company is currently enrolling patients in a U.S. trial of DCVax-L to treat glioblastoma multiforme (GBM), the most lethal form of brain cancer. GBM is difficult to treat, as the tumor cells are resistant to conventional therapies, and most drugs cannot cross the blood-brain barrier. Most patients die within 15 months of diagnosis.

To date, the clinical data for DCVax-L have shown a median survival of 33.8 months (and continuing) for patients treated with DCVax-L, with 9 of 19 patients still alive from 8-82 months after initial surgery. Most of these patients showed no evidence of tumor recurrence. NWBO is partnered with the Fraunhofer Institute, Europe’s largest applied-research organization, and King’s College London on the development of DCVax-L.

NWBO also plans to initiate a Phase III trial of DCVax-Prostate in patients with late-stage prostate cancer. In an earlier clinical trial, DCVax-Prostate significantly increased the median survival time compared to chemotherapy and a key competitor, Dendreon’s (NasdaqGS: DNDN) Provenge.

A third product candidate, DCVax-Direct, addresses inoperable solid tumor cancers, which are cancers located in the tissues of the body. In pre-clinical animal trials, DCVax-Direct shrank and eliminated tumors not only at the injection site, but also on the opposite side of the body, indicating a systemic immune response. Additionally, when the animals were later injected with cancer cells, they didn’t redevelop cancer. The Company plans to initiate Phase I/II human clinical trials of DCVax-Direct.

NWBO offers investors a unique value proposition: a development-stage biotech company trading in the low $3 range, with two potential game-changing products in Phase III trials. Major recent accomplishments position NWBO for inflection: a new listing on Nasdaq, a comprehensive balance sheet clean-up that retired more than $36 million in debt, and the completion of a major new financing. To learn more about NWBO, watch our recent interview with CEO Linda Powers:

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

One fast-growing company in this space is MusclePharm (OTCQB: MSLP). Founded in 2008 in CEO Brad Pyatt’s garage, MSLP has achieved triple-digit annual revenue growth since its inception, growing from $1.4 million in 2009 to an estimated $78 million in 2012. The Company projects $100 million in revenue for 2013.

During 2012, management focused on cutting costs, eliminating toxic debt overhang, and cleaning up the Company’s balance sheet. MSLP recently paid off its remaining debt after completing a $12 million round of financing led by The Frost Group, headed by billionaire investor Dr. Phillip Frost. Now debt free and growing rapidly, MSLP is focused on expanding its operations and achieving profitability in 2013.

MSLP’s products are sold in over 110 countries and more than 10,000 U.S. retail outlets, including GNC, Vitamin Shoppe and Vitamin World. The Company recently won the 2012 GNC “Rising Star” vendor award in the sports category. The GNC Rising Star award is given annually to an emerging brand that has demonstrated strong sales growth in a short time period. MSLP’s products are also sold in more than 100 online stores and consistently rank among Bodybuilding.com’s top 50 best sellers.

A former NFL player for the Indianapolis Colts, Mr. Pyatt continues to leverage his sports experience to bring high-quality supplements to the market. The Company’s exponential sales growth is a testament to the effectiveness of MSLP’s products, which are used by athletes nationwide to increase strength, endurance, and energy. MSLP is the official nutritional supplement sponsor of the Ultimate Fighting Championship, the largest mixed martial arts promotion company, which hosts most of the top-ranked fighters in the world.

The Company’s highly experienced medical and scientific team sets MSLP apart from others in its space. MSLP employs six full-time scientists, and its chief medical director is one of the leading sports nutrition doctors in the country. MSLP’s products are free of banned substances and undergo rigorous testing at the company’s state-of-the-art sports science center and research institute in Denver.

To learn more about MSLP, watch our recent “Money Report” interview with founder and CEO Brad Pyatt:

MSLP currently trades in the $5.00 to $6.00 range. With a large, devoted, growing customer base, a clean balance sheet, and profitability on the horizon, the stock is poised for significant appreciation in 2013. Now is the time for investors to follow Dr. Frost’s lead and start building a position in MSLP. Don’t miss out.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

The purpose of this paper is to make the case for small and micro-cap value stocks as an advantaged asset class. We believe the historical body of evidence shows just such an advantage, and that a rational analysis of that past performance provides evidence that this outperformance is likely to continue. While there are also plenty of risks that accompany investing in small and micro-cap stocks, we believe the inherent advantage embedded within this space makes it a fruitful pond for investors to fish in, and one in which skilled investment managers have the potential to make a big difference in performance over time.

Read the full paper here.
(Firefox users may need to download PDF Viewer plugin to view paper.)